Mesa Laboratories, Inc.
NASDAQ:MLABHardware, Equipment & Parts
-$0.15 today
- Market cap
- $774.56M
- Beta
- 0.93
- P/E (TTM)
- 78.3
- EPS (TTM)
- $1.21
- Dividend yield
- 0.68%
Volume 0.07M
Average 0.16M
MLAB Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Mesa Laboratories, Inc.NASDAQ: MLAB
Capital Expenditures · Q4 FY2026 · quarter ended Mar 2026
Capital expenditures turns positive
Q4 FY2026 capital expenditures was $2.83M, compared with -$1.01M a year earlier. Trailing-twelve-month capital expenditures was $0. Over 3 fiscal years it compounded at -10.6% a year.
Context
- Capital expenditures amounted to 1.3% of revenue in FY2026, down 0.6 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly capital expenditures holds near $2.83M or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2026
- (3.25M) USD
- Year-over-year change
- +27.8%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | (3.25M) | +27.8% |
| FY2025 | 2025-03-31 | (4.5M) | -75.3% |
| FY2024 | 2024-03-31 | (2.57M) | +43.5% |
| FY2023 | 2023-03-31 | (4.54M) | -2.5% |
| FY2022 | 2022-03-31 | (4.43M) | — |
Capital Expenditures vs competitors
How MLAB compares with its peers on the latest reported figures
- MLAB's LTM Mar 2026 capital expenditures of $0 is the smallest of the 11 companies compared; the peer median is $49.46M.
- Its year-over-year change of +100.0% is the highest of 11, against a peer median of -20.6%.
- Capital expenditures amounts to 0.0% of revenue for MLAB, versus a peer median of 4.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.73B | +12.2% | -12.1% | 3.6% | |
| LTM Jul 2026 | $342M | -16.0% | +11.8% | 4.6% | |
| LTM Jun 2026 | $206.77M | +15.7% | +10.4% | 9.8% | |
| LTM Jun 2026 | $139.5M | -25.3% | +11.3% | 5.4% | |
| LTM Jul 2026 | $69.52M | -14.8% | -5.0% | 2.4% | |
| LTM Sep 2026 | $29.4M | +8.1% | -9.0% | 2.4% | |
| LTM Jun 2026 | $9.85M | -58.2% | -8.4% | 4.7% | |
| LTM Jun 2026 | $5.65M | -43.9% | -64.4% | 0.9% | |
| LTM Mar 2026 | $4.37M | -49.8% | -45.7% | 2.7% | |
| LTM Mar 2026 | $3.82M | -69.8% | +29.5% | 4.4% | |
| LTM Mar 2026 | $0 | +100.0% | -10.6% | 0.0% | |
| Peer median (excluding MLAB) | $49.46M | -20.6% | -6.7% | 4.0% | |
Competitors are the stored peer set for MLAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Net Income | 1.87M | 930K | (254.25M) | (1.97M) | 6.71M |
| Depreciation & Amortization | 25.07M | 33.13M | 31.57M | 24.53M | 23.27M |
| Deferred Income Tax | 128K | (3.49M) | (28.42M) | (72K) | (1.29M) |
| Stock-Based Compensation | 11.39M | 12.54M | 11.94M | 13.14M | 17.87M |
| Change in Working Capital | (7.19M) | (17.11M) | 5.97M | 6.9M | (4.99M) |
| Accounts Receivables | (6.75M) | (2.12M) | 4.94M | (2.93M) | (3.21M) |
| Inventory | (1.05M) | (10.18M) | 2.56M | 1.15M | (4.43M) |
| Accounts Payables | 1.37M | (1.55M) | (97K) | (388K) | (1.2M) |
| Other Working Capital | (765K) | (3.26M) | (1.43M) | 9.06M | 3.85M |
| Other Non-Cash Items | 7.96M | 1.99M | 277.32M | 4.28M | 1.26M |
| Operating Cash Flow | 39.22M | 27.98M | 44.13M | 46.81M | 42.83M |
| Capital Expenditures | (4.43M) | (4.54M) | (2.57M) | (4.5M) | (3.25M) |
| Acquisitions (Net) | (300.79M) | (4.95M) | (78.74M) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | (250K) | 0 |
| Investing Cash Flow | (305.23M) | (9.49M) | (81.31M) | (4.5M) | (3.25M) |
| Debt Repayment | 49M | (36M) | 37.5M | (42.35M) | (26.75M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (3.34M) | (3.41M) | (3.45M) | (3.47M) | (3.52M) |
| Other Financing Activities | 6.92M | 6.08M | (1.22M) | 1.31M | (11.58M) |
| Financing Cash Flow | 52.58M | (33.33M) | 32.84M | (44.51M) | (41.85M) |
| Effect of Forex Changes | (1.09M) | (1.6M) | (359K) | 1.31M | 1.88M |
| Net Change in Cash | (214.52M) | (16.44M) | (4.7M) | (893K) | (393K) |
| Free Cash Flow | 34.79M | 23.44M | 41.57M | 42.31M | 39.58M |
Mesa Laboratories, Inc.
NASDAQ:MLAB
Intrinsic Alpha fair value
Locked
Current Price
$137.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.